Parkinson's Disease Tulip


advertisement
 
 
Thread Tools Display Modes
Prev Previous Post   Next Post Next
Old 10-03-2016, 10:06 AM #1
olsen's Avatar
olsen olsen is offline
Senior Member
 
Join Date: Aug 2006
Posts: 1,860
15 yr Member
olsen olsen is offline
Senior Member
olsen's Avatar
 
Join Date: Aug 2006
Posts: 1,860
15 yr Member
Default Cancer drug potential for reducing a-synuclien aggregates

A new protein capable of reducing the risk of Parkinson's disease identified | TheHealthSite.com


LAG3 inhibitor made by Norvartis is in Phase 1/2 clinical trial for solid tumor cancers.

Beyond PD-1[mdash]selected immuno-oncology drug therapies in development : Immuno-oncology moves beyond PD-1 : Nature Biotechnology : Nature Research
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices.

~ Jean-Martin Charcot


The future is already here — it's just not very evenly distributed. William Gibson
olsen is offline   Reply With QuoteReply With Quote
"Thanks for this!" says:
eds195 (10-03-2016), jeffreyn (10-03-2016)
 

Tags
1/2, cancers, clinical, phase, solid


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off



All times are GMT -5. The time now is 01:24 PM.

Powered by vBulletin • Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.

vBulletin Optimisation provided by vB Optimise v2.7.1 (Lite) - vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.
 

NeuroTalk Forums

Helping support those with neurological and related conditions.

 

The material on this site is for informational purposes only,
and is not a substitute for medical advice, diagnosis or treatment
provided by a qualified health care provider.


Always consult your doctor before trying anything you read here.